Lactic Acid Bacteria Reduce Plasma Lipopolysaccharide Levels

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Metabolic endotoxemia, characterized by elevated levels of lipopolysaccharides in the body due to a high-fat diet, is not effectively addressed by existing technologies, leading to potential inflammation and metabolic disorders.

Innovation Solution

The use of lactic acid bacteria, such as Lactobacillus acidophilus and Bifidobacterium species, in food products, dietary supplements, or medicaments to reduce bacterial translocation, adhesion, and absorption of Gram-negative bacteria, thereby lowering plasma lipopolysaccharide levels and mitigating endotoxemia.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Use of energy by moving object

If a high-fat diet is consumed, then energy intake is increased, but plasma lipopolysaccharide levels increase leading to metabolic endotoxemia

Engineering Contradiction:

Improveenergy intakeVSAvoidplasma lipopolysaccharide levels

Core Design Contradiction:

Use of energy by moving objectVSObject-affected harmful factors

Solution Approach 1:

Probiotic bacteria serve as an intermediary agent that modulates the interaction between dietary fats and the intestinal barrier. These bacteria strengthen gut barrier function and reduce bacterial translocation, thereby preventing the conversion of high-fat diet consumption into metabolic endotoxemia while allowing continued energy intake

Inventive Principle:

Principle #24Intermediary (Mediator)

2Adaptability or versatility

If intestinal permeability increases, then bacterial translocation is facilitated, but this leads to elevated endotoxemia and inflammation

Engineering Contradiction:

Improveintestinal permeabilityVSAvoidbacterial translocation

Core Design Contradiction:

Adaptability or versatilityVSObject-affected harmful factors

Solution Approach 1:

Probiotic bacteria are administered in advance to prevent and repair intestinal barrier dysfunction before significant bacterial translocation occurs. These bacteria colonize the gut, strengthen tight junctions, and maintain barrier integrity, thereby preventing the harmful effects of increased permeability while allowing physiological adaptability

Inventive Principle:

Principle #10Preliminary action

3Ease of operation

If Gram-negative bacteria translocate into the body, then bacterial circulation occurs, but this serves as a source of LPS and causes endotoxemia

Engineering Contradiction:

Improvebacterial circulationVSAvoidLPS source

Core Design Contradiction:

Ease of operationVSObject-generated harmful factors

Solution Approach 1:

The patent converts the potential harm of Gram-negative bacteria into a benefit by using probiotic bacteria to competitively inhibit pathogenic Gram-negative bacteria. The probiotics occupy ecological niches, consume available nutrients, and stimulate immune responses that prevent pathogenic bacteria from translocating and releasing LPS, thereby transforming the microbial environment from harmful to beneficial

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS10543239B2Lactic acid bacteria and <i>bifidobacteria </i>for treating endotoxemia

Publication Date: 2020.01.28 INT N&H DENMARK APS

AI summary

The invention relates to use of a bacterium selected from a lactic acid bacterium, a Bifidobacterium or a mixture of any thereof for treating metabolic endotoxemia, inhibiting bacterial translocation and regulating lipid absorption in a mammal.